search
Back to results

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (BrigHTN)

Primary Purpose

Resistant Hypertension

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
CIN-107
Placebo
Sponsored by
CinCor Pharma, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Resistant Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Is on a stable regimen of ≥ 3 antihypertensive agents (one of which is a diuretic) for at least 4 weeks prior to randomization;
  • Be at least 70% compliant to their anti-hypertensive medication regimen;
  • Has a seated BP ≥ 130/80 mmHg;
  • Agrees to comply with the contraception and reproduction restrictions of the study; and
  • Able to understand and willing to comply with all study visits, procedures, restrictions, and provide written informed consent according to institutional and regulatory guidelines.

Exclusion Criteria:

  • Has a seated SBP ≥ 180 mmHg or DBP ≥ 110 mmHg;
  • Has a body mass index (BMI) > 40 kg/m2;
  • Has an upper arm circumference < 7 or > 17 inches;
  • Has been on night shifts at any time during the 4 weeks before Screening;
  • Is using a beta blocker for any primary indication other than systemic hypertension (eg, migraine headache);
  • Is not willing or not able to discontinue an MRA or a potassium sparing diuretic as part of an existing antihypertensive regimen;
  • Is not willing or not able to discontinue taking a potassium supplement;
  • Has documented estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m2
  • Has known and documented New York Heart Association stage III or IV chronic heart failure
  • Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before Screening;
  • Has known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease diagnosed from a prior echocardiogram;
  • Major cardiac surgery (eg, CABG, valve replacement), peripheral arterial bypass surgery, or PCI within 6 months before Screening;
  • Has chronic permanent atrial fibrillation;
  • Has uncontrolled diabetes with glycosylated hemoglobin > 9.5% at Screening;
  • Has planned dialysis or kidney transplant during the course of this study;
  • Potassium < 3.5 mEq/L;
  • Potassium > 5.0 mEq/L;
  • Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen;
  • Has typical consumption of ≥14 alcoholic drinks weekly.

Sites / Locations

  • CinCor Site 16
  • CinCor Site 38
  • CinCor Site 61
  • CinCor Site 90
  • CinCor Site 82
  • CinCor Site 91
  • CinCor Site 25
  • CinCor Site 73
  • CinCor Site 36
  • CinCor Site 34
  • CinCor Site 14
  • CinCor Site 28
  • CinCor Site 19
  • CinCor Site 32
  • CinCor Site 44
  • CinCor Site 66
  • CinCor Site 56
  • CinCor Site 30
  • CinCor Site 13
  • CinCor Site 74
  • CinCor Site 22
  • CinCor Site 20
  • CinCor Site 1
  • CinCor Site 84
  • CinCor Site 70
  • CinCor Site 89
  • CinCor Site 94
  • CinCor Site 5
  • CinCor Site 9
  • CinCor Site 23
  • CinCor Site 88
  • CinCor Site 71
  • CinCor Site 11
  • CinCor Site 15
  • CinCor Site 81
  • CinCor Site 49
  • CinCor Site 35
  • CinCor Site 58
  • CinCor Site 54
  • CinCor Site 29
  • CinCor Site 24
  • CinCor Site 69
  • CinCor Site 64
  • CinCor Site 75
  • CinCor Site 65
  • CinCor Site 52
  • CinCor Site 21
  • CinCor Site 92
  • CinCor Site 50
  • CinCor Site 45
  • CinCor Site 47
  • CinCor Site 31
  • CinCor Site 4
  • CinCor Site 55
  • CinCor Site 59
  • CinCor Site 6
  • CinCor Site 7
  • CinCor Site 86
  • CinCor Site 43
  • CinCor Site 39
  • CinCor Site 97
  • CinCor Site 42
  • CinCor Site 27
  • CinCor Site 80
  • CinCor Site 79
  • CinCor Site 87
  • CinCor Site 2
  • CinCor Site 72
  • CinCor Site 46
  • CinCor Site 93
  • CinCor Site 37
  • CinCor Site 85
  • CinCor Site 48
  • CinCor Site 3
  • CinCor Site 77
  • CinCor Site 8
  • CinCor Site 33
  • CinCor Site 76
  • CinCor Site 41
  • CinCor Site 51

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

CIN-107 0.5mg

CIN-107 1mg

CIN-107 2mg

Placebo

Arm Description

Subjects received CIN-107 0.5 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.

Subjects received CIN-107 1 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.

Subjects received CIN-107 2 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.

Subjects received placebo tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.

Outcomes

Primary Outcome Measures

Change From Baseline in Mean Seated Systolic BP (SBP)

Secondary Outcome Measures

Change From Baseline in Mean Seated Diastolic BP (DBP)
The Percentage of Patients Achieving a Seated BP Response <130/80 mmHg

Full Information

First Posted
August 17, 2020
Last Updated
July 10, 2023
Sponsor
CinCor Pharma, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04519658
Brief Title
A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
Acronym
BrigHTN
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (rHTN)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
October 12, 2020 (Actual)
Primary Completion Date
June 14, 2022 (Actual)
Study Completion Date
June 14, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CinCor Pharma, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of treatment in patients with treatment-resistant hypertension (rHTN).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Resistant Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
275 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CIN-107 0.5mg
Arm Type
Experimental
Arm Description
Subjects received CIN-107 0.5 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
Arm Title
CIN-107 1mg
Arm Type
Experimental
Arm Description
Subjects received CIN-107 1 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
Arm Title
CIN-107 2mg
Arm Type
Experimental
Arm Description
Subjects received CIN-107 2 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects received placebo tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
Intervention Type
Drug
Intervention Name(s)
CIN-107
Other Intervention Name(s)
baxdrostat
Intervention Description
CIN-107 tablets by mouth once daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
placebo tablets by mouth once daily
Primary Outcome Measure Information:
Title
Change From Baseline in Mean Seated Systolic BP (SBP)
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean Seated Diastolic BP (DBP)
Time Frame
12 weeks
Title
The Percentage of Patients Achieving a Seated BP Response <130/80 mmHg
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is on a stable regimen of ≥ 3 antihypertensive agents (one of which is a diuretic) for at least 4 weeks prior to randomization; Be at least 70% compliant to their anti-hypertensive medication regimen; Has a seated BP ≥ 130/80 mmHg; Agrees to comply with the contraception and reproduction restrictions of the study; and Able to understand and willing to comply with all study visits, procedures, restrictions, and provide written informed consent according to institutional and regulatory guidelines. Exclusion Criteria: Has a seated SBP ≥ 180 mmHg or DBP ≥ 110 mmHg; Has a body mass index (BMI) > 40 kg/m2; Has an upper arm circumference < 7 or > 17 inches; Has been on night shifts at any time during the 4 weeks before Screening; Is using a beta blocker for any primary indication other than systemic hypertension (eg, migraine headache); Is not willing or not able to discontinue an MRA or a potassium sparing diuretic as part of an existing antihypertensive regimen; Is not willing or not able to discontinue taking a potassium supplement; Has documented estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m2 Has known and documented New York Heart Association stage III or IV chronic heart failure Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before Screening; Has known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease diagnosed from a prior echocardiogram; Major cardiac surgery (eg, CABG, valve replacement), peripheral arterial bypass surgery, or PCI within 6 months before Screening; Has chronic permanent atrial fibrillation; Has uncontrolled diabetes with glycosylated hemoglobin > 9.5% at Screening; Has planned dialysis or kidney transplant during the course of this study; Potassium < 3.5 mEq/L; Potassium > 5.0 mEq/L; Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen; Has typical consumption of ≥14 alcoholic drinks weekly.
Facility Information:
Facility Name
CinCor Site 16
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
CinCor Site 38
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294-0007
Country
United States
Facility Name
CinCor Site 61
City
Saraland
State/Province
Alabama
ZIP/Postal Code
36571
Country
United States
Facility Name
CinCor Site 90
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85715
Country
United States
Facility Name
CinCor Site 82
City
Anaheim
State/Province
California
ZIP/Postal Code
92805
Country
United States
Facility Name
CinCor Site 91
City
Granada Hills
State/Province
California
ZIP/Postal Code
91344
Country
United States
Facility Name
CinCor Site 25
City
Lincoln
State/Province
California
ZIP/Postal Code
95821
Country
United States
Facility Name
CinCor Site 73
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
CinCor Site 36
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
CinCor Site 34
City
Lynwood
State/Province
California
ZIP/Postal Code
90262
Country
United States
Facility Name
CinCor Site 14
City
San Dimas
State/Province
California
ZIP/Postal Code
91773
Country
United States
Facility Name
CinCor Site 28
City
Santa Ana
State/Province
California
ZIP/Postal Code
92705
Country
United States
Facility Name
CinCor Site 19
City
Spring Valley
State/Province
California
ZIP/Postal Code
91978
Country
United States
Facility Name
CinCor Site 32
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
Facility Name
CinCor Site 44
City
West Hills
State/Province
California
ZIP/Postal Code
91405
Country
United States
Facility Name
CinCor Site 66
City
Whittier
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
CinCor Site 56
City
Stamford
State/Province
Connecticut
ZIP/Postal Code
06905
Country
United States
Facility Name
CinCor Site 30
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33765
Country
United States
Facility Name
CinCor Site 13
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33912
Country
United States
Facility Name
CinCor Site 74
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33013
Country
United States
Facility Name
CinCor Site 22
City
Homestead
State/Province
Florida
ZIP/Postal Code
33166
Country
United States
Facility Name
CinCor Site 20
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
CinCor Site 1
City
Jupiter
State/Province
Florida
ZIP/Postal Code
33458
Country
United States
Facility Name
CinCor Site 84
City
Lake Worth
State/Province
Florida
ZIP/Postal Code
33467
Country
United States
Facility Name
CinCor Site 70
City
Miami
State/Province
Florida
ZIP/Postal Code
33012
Country
United States
Facility Name
CinCor Site 89
City
Miami
State/Province
Florida
ZIP/Postal Code
33032
Country
United States
Facility Name
CinCor Site 94
City
Miami
State/Province
Florida
ZIP/Postal Code
33033
Country
United States
Facility Name
CinCor Site 5
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
CinCor Site 9
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33709
Country
United States
Facility Name
CinCor Site 23
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
CinCor Site 88
City
Winter Haven
State/Province
Florida
ZIP/Postal Code
33880
Country
United States
Facility Name
CinCor Site 71
City
Suwanee
State/Province
Georgia
ZIP/Postal Code
30024
Country
United States
Facility Name
CinCor Site 11
City
Meridian
State/Province
Idaho
ZIP/Postal Code
83642
Country
United States
Facility Name
CinCor Site 15
City
Addison
State/Province
Illinois
ZIP/Postal Code
60101
Country
United States
Facility Name
CinCor Site 81
City
Arlington Heights
State/Province
Illinois
ZIP/Postal Code
60005
Country
United States
Facility Name
CinCor Site 49
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
CinCor Site 35
City
Morton
State/Province
Illinois
ZIP/Postal Code
61550
Country
United States
Facility Name
CinCor Site 58
City
Evansville
State/Province
Indiana
ZIP/Postal Code
47714
Country
United States
Facility Name
CinCor Site 54
City
West Des Moines
State/Province
Iowa
ZIP/Postal Code
50266
Country
United States
Facility Name
CinCor Site 29
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40503
Country
United States
Facility Name
CinCor Site 24
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40509
Country
United States
Facility Name
CinCor Site 69
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70119
Country
United States
Facility Name
CinCor Site 64
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71101
Country
United States
Facility Name
CinCor Site 75
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
CinCor Site 65
City
Elkridge
State/Province
Maryland
ZIP/Postal Code
21075
Country
United States
Facility Name
CinCor Site 52
City
Roseville
State/Province
Michigan
ZIP/Postal Code
48066
Country
United States
Facility Name
CinCor Site 21
City
Troy
State/Province
Michigan
ZIP/Postal Code
48085
Country
United States
Facility Name
CinCor Site 92
City
Hattiesburg
State/Province
Mississippi
ZIP/Postal Code
39401
Country
United States
Facility Name
CinCor Site 50
City
Olive Branch
State/Province
Mississippi
ZIP/Postal Code
38654
Country
United States
Facility Name
CinCor Site 45
City
Butte
State/Province
Montana
ZIP/Postal Code
59701
Country
United States
Facility Name
CinCor Site 47
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89119
Country
United States
Facility Name
CinCor Site 31
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87102
Country
United States
Facility Name
CinCor Site 4
City
Bronx
State/Province
New York
ZIP/Postal Code
10455
Country
United States
Facility Name
CinCor Site 55
City
Johnson City
State/Province
New York
ZIP/Postal Code
13901
Country
United States
Facility Name
CinCor Site 59
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45212
Country
United States
Facility Name
CinCor Site 6
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45246
Country
United States
Facility Name
CinCor Site 7
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45246
Country
United States
Facility Name
CinCor Site 86
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45439
Country
United States
Facility Name
CinCor Site 43
City
Beaver
State/Province
Pennsylvania
ZIP/Postal Code
15066
Country
United States
Facility Name
CinCor Site 39
City
Myrtle Beach
State/Province
South Carolina
ZIP/Postal Code
29588
Country
United States
Facility Name
CinCor Site 97
City
Jackson
State/Province
Tennessee
ZIP/Postal Code
38305
Country
United States
Facility Name
CinCor Site 42
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37920
Country
United States
Facility Name
CinCor Site 27
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
CinCor Site 80
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75006
Country
United States
Facility Name
CinCor Site 79
City
Dallas
State/Province
Texas
ZIP/Postal Code
75234
Country
United States
Facility Name
CinCor Site 87
City
Friendswood
State/Province
Texas
ZIP/Postal Code
77089
Country
United States
Facility Name
CinCor Site 2
City
Houston
State/Province
Texas
ZIP/Postal Code
77040
Country
United States
Facility Name
CinCor Site 72
City
Houston
State/Province
Texas
ZIP/Postal Code
77054
Country
United States
Facility Name
CinCor Site 46
City
Hurst
State/Province
Texas
ZIP/Postal Code
76054
Country
United States
Facility Name
CinCor Site 93
City
Kerville
State/Province
Texas
ZIP/Postal Code
78028
Country
United States
Facility Name
CinCor Site 37
City
McAllen
State/Province
Texas
ZIP/Postal Code
78503
Country
United States
Facility Name
CinCor Site 85
City
Sugar Land
State/Province
Texas
ZIP/Postal Code
77479
Country
United States
Facility Name
CinCor Site 48
City
Draper
State/Province
Utah
ZIP/Postal Code
84020
Country
United States
Facility Name
CinCor Site 3
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84107
Country
United States
Facility Name
CinCor Site 77
City
Alexandria
State/Province
Virginia
ZIP/Postal Code
22304
Country
United States
Facility Name
CinCor Site 8
City
Burke
State/Province
Virginia
ZIP/Postal Code
22015
Country
United States
Facility Name
CinCor Site 33
City
Manassas
State/Province
Virginia
ZIP/Postal Code
20110
Country
United States
Facility Name
CinCor Site 76
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23510
Country
United States
Facility Name
CinCor Site 41
City
Olympia
State/Province
Washington
ZIP/Postal Code
98502
Country
United States
Facility Name
CinCor Site 51
City
Kenosha
State/Province
Wisconsin
ZIP/Postal Code
60031
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
36342143
Citation
Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ; BrigHTN Investigators. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7.
Results Reference
background

Learn more about this trial

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

We'll reach out to this number within 24 hrs